CA2162921A1 - Derives du carbazole avec activite inhibitrice de la 17,20-lyase - Google Patents

Derives du carbazole avec activite inhibitrice de la 17,20-lyase

Info

Publication number
CA2162921A1
CA2162921A1 CA002162921A CA2162921A CA2162921A1 CA 2162921 A1 CA2162921 A1 CA 2162921A1 CA 002162921 A CA002162921 A CA 002162921A CA 2162921 A CA2162921 A CA 2162921A CA 2162921 A1 CA2162921 A1 CA 2162921A1
Authority
CA
Canada
Prior art keywords
compound
formula
group
carbazole
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002162921A
Other languages
English (en)
Inventor
Peter Clive Cherry
John Derek Cocker
Andrew David Searle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2162921A1 publication Critical patent/CA2162921A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention se rapporte à des dérivés de carbazole substitués, à des procédés destinés à leur préparation, à des compositions pharmaceutiques les contenant ainsi qu'à leur utilisation à des fins médicales pour la réduction des niveaux d'oestrogènes et/ou d'androgènes. L'invention concerne particulièrement des composés de la formule (I), dans laquelle R1 et R4 représentent chacun indépendamment un atome d'hydrogène ou un groupe C1-6 alkyle; tous les R2 peuvent être identiques ou différents et représentent un groupe d'enlèvement d'électrons; tous les R3 peuvent être identiques ou différents et représentent un groupe d'enlèvement d'électrons; R5 représente un groupe de la formule (a), (b) ou (c); R6 représente un atome d'halogène, un groupe C1-6 alkyle ou un groupe C1-6 alcoxy; m vaut zéro ou un entier de 1 à 4; n vaut zéro ou un entier de 1 à 3; et p vaut zéro, 1 ou 2. Des solvants et sels pharmaceutiquement acceptables de ces composés sont également décrits.
CA002162921A 1993-05-21 1994-05-19 Derives du carbazole avec activite inhibitrice de la 17,20-lyase Abandoned CA2162921A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939310635A GB9310635D0 (en) 1993-05-21 1993-05-21 Chemical compounds
GB9310635.9 1993-05-21
PCT/EP1994/001613 WO1994027989A1 (fr) 1993-05-21 1994-05-19 Derives de carbazole a activite d'inhibition de 17,20-lyase

Publications (1)

Publication Number Publication Date
CA2162921A1 true CA2162921A1 (fr) 1994-12-08

Family

ID=10736007

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002162921A Abandoned CA2162921A1 (fr) 1993-05-21 1994-05-19 Derives du carbazole avec activite inhibitrice de la 17,20-lyase

Country Status (19)

Country Link
EP (1) EP0699196A1 (fr)
JP (1) JPH08510455A (fr)
CN (1) CN1126473A (fr)
AU (1) AU6928794A (fr)
BG (1) BG100154A (fr)
CA (1) CA2162921A1 (fr)
CZ (1) CZ305195A3 (fr)
FI (1) FI955587A0 (fr)
GB (1) GB9310635D0 (fr)
HU (1) HUT73790A (fr)
IL (1) IL109703A0 (fr)
NO (1) NO954681L (fr)
OA (1) OA10195A (fr)
PE (1) PE31195A1 (fr)
PL (1) PL311702A1 (fr)
SK (1) SK142495A3 (fr)
TW (1) TW279866B (fr)
WO (1) WO1994027989A1 (fr)
ZA (1) ZA943494B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960704852A (ko) * 1993-09-30 1996-10-09 오노다 마사요시 아졸 유도체 및 이의 약제학적 조성물 (Azole derivative and pharmaceutical composition thereof)
WO1996014090A1 (fr) * 1994-11-07 1996-05-17 Janssen Pharmaceutica N.V. Compositions comprenant des carbazoles et des cyclodextrines
AU702406B2 (en) * 1995-03-01 1999-02-18 Yamanouchi Pharmaceutical Co., Ltd. Imidazole derivatives and medicinal composition thereof
ATE231128T1 (de) * 1997-02-21 2003-02-15 Takeda Chemical Industries Ltd Verbindungen mit kondensierten ringen, verfahren zu ihrer herstellung und ihre anwendung
CN100572363C (zh) 2000-11-17 2009-12-23 武田药品工业株式会社 咪唑衍生物、其制备方法及其用途
US6960586B2 (en) 2000-11-20 2005-11-01 Takeda Pharmaceutical Company Limited Imidazole derivatives, process for their preparation and their use
CA2431171A1 (fr) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Derives thiazole substitues porteurs de groupes 3-pyridyl, procede d'elaboration et leur utilisation
MX2007015905A (es) * 2005-06-24 2008-03-06 Lilly Co Eli Derivados de tetrahidrocarbazol utiles como moduladores de receptor de androgeno (sarm).
GB0525323D0 (en) 2005-12-13 2006-01-18 Sterix Ltd Compound
US8093279B2 (en) 2005-12-13 2012-01-10 Gillian Reed, legal representative Compound
CN100586932C (zh) * 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 抗肿瘤化合物及其制备方法
GEP20156250B (en) 2009-06-26 2015-02-25 Novartis Ag 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
CA2788907A1 (fr) * 2010-02-04 2011-08-11 Radius Health, Inc. Modulateurs selectifs du recepteur des androgenes
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
JP5998137B2 (ja) 2010-08-04 2016-09-28 ペルフィキュア ファーマシューティカルズ，インコーポレイテッド 前立腺癌を処置するための併用療法
EP2627648A1 (fr) 2010-09-16 2013-08-21 Novartis AG INHIBITEURS DE LA 17a-HYDROXYLASE/C17,20-LYASE
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
ES2656218T3 (es) 2011-04-28 2018-02-26 Novartis Ag Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
WO2014158875A1 (fr) 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Nouvelle thérapie pour le carcinome de la prostate
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US10093620B2 (en) 2014-09-12 2018-10-09 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
LT3474841T (lt) 2016-06-22 2022-06-10 Ellipses Pharma Ltd Ar+ krūties vėžio gydymo būdai
EP3528799A1 (fr) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Compositions pharmaceutiques de 5-hydroxy-2-méthylnaphtalène-1, 4-dione
LT3565542T (lt) 2017-01-05 2024-07-10 Radius Pharmaceuticals, Inc. Polimorfinės rad1901-2hcl formos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229934B2 (en) * 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
ZA943494B (en) 1995-01-23
BG100154A (en) 1996-07-31
EP0699196A1 (fr) 1996-03-06
GB9310635D0 (en) 1993-07-07
FI955587A (fi) 1995-11-20
SK142495A3 (en) 1996-06-05
TW279866B (fr) 1996-07-01
FI955587A0 (fi) 1995-11-20
IL109703A0 (en) 1994-08-26
JPH08510455A (ja) 1996-11-05
OA10195A (en) 1996-12-18
AU6928794A (en) 1994-12-20
PL311702A1 (en) 1996-03-04
NO954681D0 (no) 1995-11-20
NO954681L (no) 1995-11-20
CN1126473A (zh) 1996-07-10
PE31195A1 (es) 1995-10-18
HUT73790A (en) 1996-09-30
WO1994027989A1 (fr) 1994-12-08
HU9503321D0 (en) 1996-01-29
CZ305195A3 (en) 1996-06-12

Similar Documents

Publication Publication Date Title
CA2162921A1 (fr) Derives du carbazole avec activite inhibitrice de la 17,20-lyase
AU654350B2 (en) Benzofuran derivatives
EP3064498B1 (fr) Dérivés pyrazolopyrimidone ou pyrrolotriazone, leur procédé de préparation, et applications pharmaceutiques associées
IE904146A1 (en) Indole Derivatives
JPH05501566A (ja) ３―置換―１―（アリールまたはアリールアルキル）―２（１ｈ）―キノリノン
WO2000066574A1 (fr) 2,1-benzisothiazoline 2,2-dioxydes
JP2707936B2 (ja) β−オキソ−β−ベンゼンプロパンチオアミド誘導体
CA2214744C (fr) Derives de 3-(bis-phenylmethylene substitue) oxindole
US5578630A (en) Heterocyclic compounds which inhibit aromatase
US6689798B2 (en) Benzofuran derivatives
JP2008513422A (ja) インドリン−２−オンピリジン誘導体、その調製及び治療上の使用
US5726196A (en) Aromatase-inhibiting composition containing azole derivative
KR102406248B1 (ko) Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물
KR102406246B1 (ko) Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도
EP0574992A1 (fr) Dérivés de 5(1,2,4-triazol-1-ylméthyl)-3H-isobenzofuran-1-one, leurs préparation et application en tant qu'inhibiteurs d'aromatase
HRP940940A2 (en) Chemical compounds
JPS6256471A (ja) 含窒素四環式化合物
KR101637416B1 (ko) 구굴스테론 유도체, 그 제조방법 및 그를 포함하는 조성물
HUT59107A (en) Process for producing new 4(5)-imidazole derivatives having aromatase inhibiting activity and pharmaceutical compositions comprising same as active ingredient
SK286757B6 (sk) 17-Metylénsteroidy, spôsob ich prípravy, farmaceutické kompozície, ktoré ich obsahujú, a ich použitie
JPS633859B2 (fr)
MXPA98004819A (en) Gonadotrop liberating hormone antagonists
EP1175413A1 (fr) 2,1-benzisothiazoline 2,2-dioxydes

Legal Events

Date Code Title Description
FZDE Discontinued